53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

Nature Structural and Molecular Biology

Volumn 17, Issue 6, 2010, Pages 688-695

  Bouwman, Peter ^a   Aly, Amal ^b   Escandell, Jose M ^c   Pieterse, Mark ^a   Bartkova, Jirina ^d   Van Der Gulden, Hanneke ^a   Hiddingh, Sanne ^a   Thanasoula, Maria ^c   Kulkarni, Atul ^b   Yang, Qifeng ^b   Haffty, Bruce G ^b   Tommiska, Johanna ^e   Blomqvist, Carl ^e   Drapkin, Ronny ^f   Adams, David J ^g   Nevanlinna, Heli ^e   Bartek, Jiri ^d,h   Tarsounas, Madalena ^c   Ganesan, Shridar ^b   Jonkers, Jos ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^h PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BINDING PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; P53 BINDING PROTEIN 1; RAD51 PROTEIN; SHORT HAIRPIN RNA; TUBULIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DISTANT METASTASIS; DNA REPAIR; DNA STRAND BREAKAGE; GENE DELETION; GENE EXPRESSION; GENOMIC INSTABILITY; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; MUTAGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSPOSON;

EID: 77953291328     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.1831     Document Type: Article

References (54)

1. Venkitaraman, A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108, 171-182 (2002).
2. Gudmundsdottir, K. & Ashworth, A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25, 5864-5874 (2006).
3. Boulton, S.J. Cellular functions of the BRCA tumour-suppressor proteins. Biochem. Soc. Trans. 34, 633-645 (2006).
4. Collins, N. et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 10, 1673-1675 (1995).
5. Smith, S.A., Easton, D.F., Evans, D.G. & Ponder, B.A. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat. Genet. 2, 128-131 (1992).
6. Johannsson, O.T. et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur. J. Cancer 33, 362-371 (1997).
7. Foulkes, W.D. et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl. Cancer Inst. 95, 1482-1485 (2003).
8. Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 100, 8418-8423 (2003).
9. Turner, N., Tutt, A. & Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 4, 814-819 (2004).
10. Evers, B. & Jonkers, J. Mouse models of BRCA1 and BRCA2 defciency: past lessons, current understanding and future prospects. Oncogene 25, 5885-5897 (2006).
11. Hakem, R., de la Pompa, J.L., Elia, A., Potter, J. & Mak, T.W. Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. Nat. Genet. 16, 298-302 (1997).
12. Cao, L. et al. A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 defciency. Mol. Cell 35, 534-541 (2009).
13. Wang, B., Matsuoka, S., Carpenter, P.B. & Elledge, S.J. 53BP1, a mediator of the DNA damage checkpoint. Science 298, 1435-1438 (2002).
14. Morales, J.C. et al. 53BP1 and p53 synergize to suppress genomic instability and lymphomagenesis. Proc. Natl. Acad. Sci. USA 103, 3310-3315 (2006).
15. Ward, I.M. et al. 53BP1 cooperates with p53 and functions as a haploinsuffcient tumor suppressor in mice. Mol. Cell. Biol. 25, 10079-10086 (2005).
16. Xu, X. et al. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat. Genet. 28, 266-271 (2001).
17. Hakem, R. et al. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 85, 1009-1023 (1996).
18. Liu, X. et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc. Natl. Acad. Sci. USA 104, 12111-12116 (2007).
19. Hameyer, D. et al. Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues. Physiol. Genomics 31, 32-41 (2007).
20. Wang, W. et al. Chromosomal transposition of PiggyBac in mouse embryonic stem cells. Proc. Natl. Acad. Sci. USA 105, 9290-9295 (2008).
21. Bartz, S.R. et al. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol. Cell. Biol. 26, 9377-9386 (2006).
22. Kastan, M.B. & Bartek, J. Cell-cycle checkpoints and cancer. Nature 432, 316-323 (2004).
23. Taylor, W.R. & Stark, G.R. Regulation of the G2/M transition by p53. Oncogene 20, 1803-1815 (2001).
24. Silver, D.P. & Livingston, D.M. Self-excising retroviral vectors encoding the Cre recombinase overcome Cre-mediated cellular toxicity. Mol. Cell 8, 233-243 (2001).
25. Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29, 418-425 (2001).
26. Jazayeri, A. et al. ATM-and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat. Cell Biol. 8, 37-45 (2006).
27. Bhattacharyya, A., Ear, U.S., Koller, B.H., Weichselbaum, R.R. & Bishop, D.K. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem. 275, 23899-23903 (2000).
28. te Riele, H., Robanus-Maandag, E. & Berns, A. Highly effcient gene targeting in embryonic stem cells through homologous recombination with isogenic DNA constructs. Proc. Natl. Acad. Sci. USA 89, 5128-5132 (1992).
29. te Riele, H., Robanus-Maandag, E., Clarke, A., Hooper, M. & Berns, A. Consecutive inactivation of both alleles of the pim-1 proto-oncogene by homologous recombination in embryonic stem cells. Nature 348, 649-651 (1990).
30. Holstege, H. et al. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res. 69, 3625-3633 (2009).
31. Manie, E. et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res. 69, 663-671 (2009).
32. Ludwig, T., Chapman, D.L., Papaioannou, V.E. & Efstratiadis, A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev. 11, 1226-1241 (1997).
33. Wang, Y. et al. Gene-expression profles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671-679 (2005).
34. Alexe, G. et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res. 67, 10669-10676 (2007).
35. Richardson, A.L. et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9, 121-132 (2006).
36. Scully, R. et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 90, 425-435 (1997).
37. Bartek, J. & Hodny, Z. SUMO boosts the DNA damage response barrier against cancer. Cancer Cell 17, 9-11 (2010).
38. Galanty, Y. et al. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature 462, 935-939 (2009).
39. Morris, J.R. et al. The SUMO modifcation pathway is involved in the BRCA1 response to genotoxic stress. Nature 462, 886-890 (2009).
40. Deng, C.X. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res. 34, 1416-1426 (2006).
41. Ward, I.M., Minn, K., van Deursen, J. & Chen, J. p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Mol. Cell. Biol. 23, 2556-2563 (2003).
42. Bunting, S.F. et al. 53BP1 inhibits homologous recombination in Brca1-defcient cells by blocking resection of DNA breaks. Cell 141, 243-254 (2010).
43. Shiotani, B. & Zou, L. Single-stranded DNA orchestrates an ATM-to-ATR switch at DNA breaks. Mol. Cell 33, 547-558 (2009).
44. Silver, D.P. et al. Effcacy of neoadjuvant Cisplatin in triple-negative breast cancer. J. Clin. Oncol. 28, 1145-1153 (2010).
45. Fong, P.C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
46. Rottenberg, S. et al. High sensitivity of BRCA1-defcient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. USA 105, 17079-17084 (2008).
47. Rottenberg, S. et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc. Natl. Acad. Sci. USA 104, 12117-12122 (2007).
48. Swisher, E.M. et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68, 2581-2586 (2008).
49. Shafee, N. et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res. 68, 3243-3250 (2008).
50. Jacobs, J.J. et al. Senescence bypass screen identifes TBX2, which represses Cdkn2a (p19(ARF)) and is amplifed in a subset of human breast cancers. Nat. Genet. 26, 291-299 (2000).
51. Tarsounas, M. et al. Telomere maintenance requires the RAD51D recombination/repair protein. Cell 117, 337-347 (2004).
52. Dirac, A.M. & Bernards, R. Reversal of senescence in mouse fbroblasts through lentiviral suppression of p53. J. Biol. Chem. 278, 11731-11734 (2003).
53. Palmero, I. & Serrano, M. Induction of senescence by oncogenic Ras. Methods Enzymol. 333, 247-256 (2001).
54. Tarsounas, M., Davies, D. & West, S.C. BRCA2-dependent and independent formation of RAD51 nuclear foci. Oncogene 22, 1115-1123 (2003).